The EPS projection of Diplomat Pharmacy, Inc. (NYSE:DPLO) for quarter ended 2016-09-30 is $0.24. Last week, the EPS forecast was $0.24 against target of $0.24, a month earlier. Two months ago, this estimate was $0.24 versus forecast of $0.24 three months earlier, implying a deviation of 0%.
Diplomat Pharmacy, Inc. (NYSE:DPLO) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 3.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 3, and 3, correspondingly.
EPS estimate downgrade for Diplomat Pharmacy, Inc. (NYSE:DPLO) in the preceding 30, 120, 60 and 90 days were 0, 4, 2, and 2, correspondingly.
Diplomat Pharmacy, Inc. (NYSE:DPLO) EPS target for the quarter closed 1 was $0.24, based on 8 recommendations. As reported on 2016-05-09 the EPS was $0.23. The change was $0.05, implying a percentage deviation of 27.78%. The projections showed a standard deviation of 0.03.
Quarterly Sales Estimates
Diplomat Pharmacy, Inc. (NYSE:DPLO) yearly sales prediction for the fiscal 2017 stands at $1624.985 and the median estimate is at $1624.985. Almost 2 analysts issued sales target.
Highest sales target is $1637.23 while the lowest target is $1612.74 showing standard deviation of 17.317%.
As many as 2 analysts have sales targets revised upside while 2 reduced sales estimates, implying a deviation of 0%.
Last month, 2 revised sales number projection on upside while 2 lowered the sales projections, implying a deviation of 0%.
A quarter ago, 2 hiked sales target and 2 reduced sales forecast. Diplomat Pharmacy, Inc. (NYSE:DPLO) announced that the deviation in forecast was 11.138%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...